Detalhe da pesquisa
1.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Oncologist
; 26(10): e1786-e1799, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196068
2.
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 21(2): 250-260, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859246
3.
Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Oncologist
; 25(4): 348-354, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32297444
4.
An Analysis of Recent FDA Oncology Scientific Publications.
Oncologist
; 25(3): 266-270, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162806
5.
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Oncologist
; 25(2): e328-e334, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043777
6.
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Oncologist
; 24(5): e180-e187, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30914464
7.
A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN.
Oncologist
; 24(12): 1510-e1265, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31350329
8.
Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions.
Clin Trials
; 16(3): 322-326, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30880446
9.
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 19(2): 229-239, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29361469
10.
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Oncologist
; 23(3): 353-359, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29242281
11.
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Oncologist
; 22(11): 1392-1399, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28835513
12.
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Oncologist
; 22(7): 873-878, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28533473
13.
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.
J Pharmacokinet Pharmacodyn
; 44(5): 403-414, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28573468
14.
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Oncologist
; 21(5): 643-50, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27026676
15.
Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
Oncologist
; 21(8): 974-80, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27328934
16.
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
Oncologist
; 20(11): 1320-5, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26446239
17.
Development, Validation, and Regulatory Considerations for a Liquid Biopsy Test.
Clin Chem
; 66(3): 408-414, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32091082
18.
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Oncologist
; 19(10): e5-11, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25170012
19.
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Oncologist
; 19(7): 774-9, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24868098
20.
Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma.
Oncologist
; 23(2): 139-142, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29180460